Supernus Pharmaceuticals | SUPN - Operating Profit


Supernus Pharmaceuticals reported $-35.25M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Abbott USD 1.85B 399M Mar/2026
ANI Pharmaceuticals USD 38.71M 9.58M Mar/2026
Aurora Cannabis CAD -35.79M 19.88M Dec/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Canopy Growth CAD -12.66M 1.64M Dec/2025
Cara Therapeutics USD -5.94M 3.55M Sep/2025
Corcept Therapeutics USD -49.6M 54.09M Mar/2026
Eisai JPY -10.31B 30.35B Mar/2026
Eli Lilly USD 9.78B 792M Mar/2026
Novo Nordisk DKK 59.62B 27.24B Mar/2026
Pacira USD 4.62M 1.43M Mar/2026
Perrigo USD 33.6M 50.8M Mar/2026
Pfizer USD 4.99B 340M Mar/2026
Supernus Pharmaceuticals USD -35.25M 49.07M Mar/2026
United Therapeutics USD 325.8M 340.4M Mar/2026
Xeris Pharmaceuticals USD 16.77M 10.04M Dec/2025